Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Lexaria Bioscience Corp. LEXX

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its mid-year update, marking significant strides both in its research and in creating value for its shareholders. In a report by Zacks Small Cap Research, the company’s … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the publishing of its groundbreaking research utilizing DehydraTECH(TM)-processed cannabidiol (DehydraTECH-CBD) in eight peer-reviewed articles in six different publications. Since 2016, the company’s patented DehydraTECH(TM) technology has repeatedly … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US

Lexaria Bioscience’s (NASDAQ: LEXX) intellectual property (“IP”) rests on a strong foundation of granted patents worldwide, a foundation that was recently strengthened by new patents granted in North America. The company, which is developing its patented DehydraTECH(TM) technology platform with … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Findings in Diabetes Animal Study and Two Other R&D Programs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, including the company’s patented DehydraTECH(TM) technology, recently reported additional findings from its diabetes animal study DIAB-A22-1, as well as updates on two other applied R&D programs for dementia (DEM-A22-1) … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company’s proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, held its 2023 Annual Meeting on the 9th of May, with shareholders voting on several agenda items, including the election of directors, appointment of auditors, approval of the stock … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Experienced Financial Professional as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankman will serve as outsourced CFO. An experienced accounting and finance professional, Shankman has held … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio of Worldwide Patents

Lexaria Bioscience Corp. (NASDAQ: LEXX), the global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology, recently announced it had received notification of four newly awarded or allowed patents. … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment